Imedex: Education is the Best Medicine®

QUICK POLL

If imatinib, nilotinib, and dasatinib are all approved for front-line therapy of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), what would you recommend as front-line therapy for a 42-year-old man who presents with high-risk CML by both the Sokal and Hasford (Euro) scoring systems and who has no matched sibling donor?

6th European Congress on Hematologic Malignancies from Clinical Science to Clinical Practice

February 26-28, 2010

Cannes, France

InterContinental Carlton Cannes

Who Should Attend

This educational activity is specifically designed for hematologists, medical oncologists, transplant oncologists, oncology fellows, oncology nurses, internists, and other physicians, physicians-in-training, and healthcare professionals involved in and/or interested in lymphoma, myeloma, related plasma cell disorders, and in the special session of 2010, acute lymphoblastic leukemia.

Educational Objectives

Demonstrate thorough knowledge and current clinical understanding of indolent lymphomas and related diseases
Discuss the role of the microenvironment in the development and disease progression of chronic lymphocytic leukemia and follicular lymphoma
Evaluate how the disease risk and age of a patient determines optimal management and the course of therapy for lymphoma
Describe the biology, management, and current treatment options of myeloma and lymphoma for front-line, salvage, and maintenance therapy, as well as therapeutic strategies to overcome relapsed/refractory disease
Evaluate the feasibility of chemotherapy, radioimmunotherapy, targeted therapy, and transplantation as treatment options for various stages of indolent lymphoma
Debate whether autologous or allogeneic stem cell transplantation is appropriate for management of mantle cell lymphoma
Employ current and novel strategies to improve diagnosis and treatment outcomes in aggressive non-Hodgkin’s lymphomas
Determine whether specific subtypes of aggressive NHL should be treated
in the same manner
Positively impact patient outcomes by assimilating diagnostic, prognostic, and molecular approaches toward optimal stratification for current and novel treatment options in acute lymphoblastic leukemia.

Andrea Biondi, MD
Catholic University of Rome
Rome, Italy

Joan Bladé, MD
University of Barcelona Hospital Clinic
Barcelona, Spain

Christian Buske, MD
University of Munich
Munich, Germany

Bertrand Coiffier, MD
Hospices Civils de Lyon
Lyon, France

Carlo Croce, MD
Ohio State University
Columbus, Ohio

Francesco d’Amore, MD, PhD
Aarhus University Hospital
Aarhus, Denmark

Martin Dreyling, MD, PhD
University Hospital Munich
Munich, Germany

Andreas Engert, MD
University Hospital of Cologne
Cologne, Germany

Christophe Fermé, MD
Institut de Cancérologie Gustave Roussy
Villejuif, France

Randy D. Gascoyne, MD
British Columbia Cancer Agency
Vancouver, Canada

Christian Geisler, MD, PhD
Nordic Lymphoma Group
Copenhagen, Denmark

Michele Ghielmini, MD
Oncologica Medica
Bellinzona, Switzerland

Paolo Ghia, MD, PhD
Universitá Vite-Salute San Raffaele
Milan, Italy

Nicola Gökbuget, MD
Goethe University Hospital
Frankfurt, Germany

Corinne Haioun, MD
Henri Mondor Hospital
Créteil, France

Michael Hallek, MD
University of Cologne
Cologne, Germany

Jean-Luc Harousseau, MD
University Hospital Hotel-Dieu
Nantes, France

Dieter Hoelzer, MD
University of Frankfurt
Frankfurt, Germany

Peter Johnson, MD
Cancer Research UK Clinical Centre
South Hampton, United Kingdom

Eva Kimby, MD, PhD
Karolinska University Hospital
Stockholm, Sweden

Veronique LeBlond, MD
University of Pierre and Hospital Pitie-Salpetriere
Paris, France

Emili Montserrat, MD
University of Barcelona
Barcelona, Spain

Nicolas Mounier, MD
CHU l'Archet
Nice, France

Antonio Palumbo, MD
University of Torino
Torino, Italy

Michael Pfreundschuh, MD
Universität des Saarlandes
Hamburg, Germany

Andreas Rosenward, MD
University of Würzburg
Würzburg, Germany

Gilles Salles, MD
Universite Claude Bernard Lyon
Hospices Civils de Lyon
Lyon, France

Jesus F. San Miguel, MD
University of Salamanca
Salamanca, Spain

Norbert Schmitz, MD
Asklepios Klinik St. George
Hamburg, Germany

Lena Specht, MD, PhD
Copenhagen University Hospital
Copenhagen, Denmark

Herve’ Tilly, MD
Groupe d’Etudes de Lymphomes de L’Adulte

Rien H.J. van Oers, MD
Academic Medical Center
Amsterdam, The Netherlands

Pier Luigi Zinzani, MD
University of Bologna
Bologna, Italy

Friday, 26 February 2010

13:00 Welcome and introduction

Session I: Myeloma
Moderator: Jesus San Miguel, MD and Bertrand Coiffier, MD

13:05
Myeloma biology overview: Insights and updates
Gareth Morgan, MD

13:20
Myeloma treatment overview: Treatment of the newly diagnosed (young and elderly) as well
as relapsed patient
Jesus San Miguel, MD

13:40
Debate: First-line treatment in the non-transplant eligible patient
Jean-Luc Harousseau, MD
Antonio Palumbo, MD

14:10
DEBATE: Best salvage therapy for the relapsed patient
Jesus San Miguel, MD
Gareth Morgan, MD

14:40
The role of VTE prophylaxis in myeloma
Antonio Palumbo, MD

15:00
Summary of the IMW consensus on response criteria and relevant outcomes
Joan Bladé, MD

15:15
Chair take-home points for the clinician

15:20
Break

Session II: Chronic Lymphocytic Leukemia
Moderator: Michael Hallek, MD and Eva Kimby, MD, PhD

15:40
MicroRNA signatures in CLL
Carlo Croce, MD

16:00
Monoclonal B-cell lymphocytosis and CLL
Paulo Ghia, MD

16:20
Case discussion: Optimal management of the low risk patient
Michael Hallek, MD

16:50
Case discussion: Optimal therapy for the high risk patient
Veronique Leblond, MD

17:20
DEBATE: Management of the double-refractory patient
Michael Hallek, MD and Emili Montserrat, MD

17:50
Panel discussion

18:00
Chair take-home points for the clinician and adjourn

Saturday, 27 February 2010

Session III: Follicular Lymphoma
Moderator: Gilles Salles, MD and Eva Kimby, MD, PhD

9:00
Role of the microenvironment in FL
Speaker invited

9:20
Overview of maintenance therapy
Gilles Salles, MD

9:40
DEBATE: Is follicular lymphoma curable?
Michele Ghielmini, MD (no)
Christian Buske, MD (yes)

10:10
DEBATE: The role of stem cell transplant in patients with relapsed follicular lymphoma
Bertrand Coiffier, MD (for)
Rien van Oers, MD (against)

10:40
Panel discussion and chair take-home points for the clinician

10:50 Break

Saturday, 27 February 2010 (...cont'd)

Session IV: Mantle Cell Lymphoma
Moderator: Martin Dreyling, MD and Eva Kimby, MD, PhD

11:10
Biology of mantle cell lymphoma
Andrew Rosenward, MD

11:30
Case discussion: Mantle cell lymphoma therapy in young and old patients
Martin Dreyling, MD

11:50
Maintenance therapy after first-line and second-line therapy in MCL
Michele Ghielmini, MD

12:10
DEBATE: Autologous versus allogeneic transplantation in mantle cell lymphoma
Christian Geisler, MD (auto)
Norbert Schmitz, MD (allo)

12:40
Panel discussion and chair take-home points for the clinician

12:50
Lunch symposium supported by Celgene Corporation

Session V: Aggressive B-cell Non-Hodgkin Lymphoma
Moderator: Bertrand Coiffier, MD and Michael Pfreundschuh, MD

14:45
Biology and treatment of bulky and mediastinal large B-cell lymphoma
Pier Luigi Zinzani, MD, PhD

15:05
DEBATE: Prevention and treatment of central nervous system disease
Michael Pfreundschuh, MD
Corinne Haioun, MD

15:35
DEBATE: Improving high-risk DLCBL in both the young and elderly
Bertrand Coiffier, MD
Michael Pfreundschuh, MD

16:05
PROPOSITION: Same treatment for germinal centre (GC) and non-GC patients?
Peter Johnson, MD (no)
Hervé Tilly, MD (yes)

16:25
Panel discussion and chair take-home points for the clinician

16:35
Break

Session VI: T-Cell Lymphoma
Moderator: Bertrand Coiffier, MD

16:55
Pathology overview of T cell lymphoma
Andreas Rosenwald, MD

17:15
Case discussion: Treatment of nasal type lymphoma (localized and disseminated)
Pier Luigi Zinzani, MD, PhD

17:35
DEBATE: Transplantation in young patients
Francesco d’Amore, MD, PhD (for)
Nicolas Mounier, MD (against)

18:05
Panel discussion and chair take-home points for the clinician

18:15
Adjourn

Sunday, 28 February 2010

Session VII: Hodgkin’s Disease
Moderator: Andreas Engert, MD

9:00
Overview: Improving efficacy and reducing toxicity of localized HD
Andreas Engert, MD

9:20
Radiation in Hodgkin’s disease
Lena Specht, MD, PhD

9:40
Treatment of relapsing patients
Christophe Fermé, MD

10:00
Allogeneic transplantation
Norbert Schmitz, MD

10:20
Panel discussion and chair take-home points for the clinician

10:30
Break

Session VIII: SPECIAL SESSION –Acute Lymphoblastic Leukemia
Moderator: Dieter Hoelzer, MD

11:00
Recent diagnostic approaches and molecular genetics in acute lymphoblastic leukemia (ALL)
Robin Foà, MD

11:25
New treatment options in adult ALL including targeted therapy
Dieter Hoelzer, MD

11:50
Update on achievements in childhood ALL
Andrea Biondi, MD

12:15
Minimal residual disease: The most prognostic parameters to stratify and treat ALL
Nicola Gökbuget, MD

12:40
Panel discussion and chair take-home points for the clinician

13:00
Adjourn

Registration Fees

Discounted.........................................€299
If payment received by 8 December 2009

Regular...............................................€399
If payment received by 18 February 2010

Full/Onsite..........................................€499
If payment received after 18 February 2010

Nurses/Residents/Students* ................€199
*proof of eligibility must accompany registration

Register:

You may register online by 18 February 2010 by visiting our website at www.imedex.com or by calling Imedex at +1 (678) 242 0906. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment:

To pre-register, registration and payment must be received no later than 18 February 2010. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906, or visit our website at www.imedex.com to ensure the program is being held as scheduled, and to confirm that the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add €50 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the Congress: EHema A138.01. An attendee is not registered until full payment is received.

Wire to: Bank of America, NA London, 1 Alie Street E1ADE London UK, Swift Code: BOFAGB22, Sort Code: 165050 Beneficiary: Bank of America Domestic Deposit #5687, Account #: 600895687029, Reference: Imedex, Inc. Account # 10726-118, IBAN: GB89 BOFA 1650 5095 6870 29.

Registration Fee Inclusions:

Registration fees include admittance to all scientific sessions, Congress materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation:

For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than 18 February 2010. The amount of registration fees remitted, minus a €90 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after 18 February 2010.

Imedex does not accept responsibility for covering travel, accommodation, or any other costs incurred by registrants in the rare event that this Congress should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

Hotel Accommodations

InterContinental Carlton Cannes
58, BD. La Croisette, BP 155
Cannes, 06414, France
Tel.: +33 4 93064006

Built in 1911, the InterContinental Carlton Cannes has evolved throughout the years as a timeless monument, a place which, day by day, combines refined service and well-being. The hotel is located on the famous Croisette Avenue and is close to the Cannes Palais des Festivals, which offers breathtaking views of the Mediterranean Sea.

For the convenience of attendees, a limited number of rooms have been reserved until 19 January 2010 at a discounted rate of €150.00 single occupancy or €175.00 double occupancy. Room rates include VAT and breakfast buffet. This rate is not guaranteed outside the Congress dates or after 19 January 2010.

To reserve your room please contact the InterContinental Carlton Cannes reservations department at +33 4 93 06 45 67/71/72. To receive the group rate, callers must identify themselves as being with the 6th European Congress in Hematologic Malignancies group. Reservation requests received after 19 January 2010 may not be guaranteed the group rate. Click here to complete a housing form.

Dear Colleague,

We are pleased to invite you to attend the 6^th European Congress on Hematologic Malignancies: From Clinical Science to Clinical Practice, which will be held on 26-28 February 2010, in beautiful and historic Cannes, France!

The focus of the 2010 Congress will be to provide a forum to review state-of-the-art and present new data on the diagnosis and management of myeloma, lymphoma and in this year’s special session, acute lymphoblastic leukemia, as well as give attendees the opportunity to exchange ideas with world-renowned opinion leaders in hematologic malignancies.

Last year’s congress, held in Munich, Germany, was attended by hematology, oncology, and other healthcare-related professionals from nearly 40 countries, all of whom increased their knowledge and have changed their approach to disease management. Their highly positive review of the educational content, quality of speakers, and presentation excellence attests to the overall satisfaction of the attendees—and the value of continuing with a comprehensive update on hematologic oncology management.

To complement the exceptional scientific experience this Congress brings, Cannes offers the perfect educational backdrop, with its Mediterranean location, quiet charm, and dedication to the arts.

We hope you will join us in this beautiful and historic city for a stimulating and enjoyable Congress, as this meeting promises to be an exciting, interactive and educational experience for all attendees!

Sincerely,
Bertrand Coiffier, MD, Chair
Eva Kimby, MD, PhD, Chair

Italian Participants

Fargo International Meetings & Conventions SRL has been appointed as the official agency for government authorization for Italian participants.
You may contact them directly at:

Fargo International Meetings & Conventions SRL
Via Piattro Maroncelli 44/66, 50137 Firenze, Italy
Tel.: +39 055 600 555
Fax: +39 055 609 078

Chairs

Bertrand Coiffier, MD
Hospices Civils de Lyon
Lyon, France

Eva Kimby, MD, PhD
Karolinska University Hospital
Stockholm, Sweden

Organizer

Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Praise from Your Colleagues:

“Conference hard to improve – it was very good”

“I found this meeting very enjoyable”

“Excellent conference”

“Thank you…interesting meeting”

“Keep up the good work”

“Thank you very much to Imedex”

“Continue in the same way!”

“Well organized”

“Thank you for high quality symposium”

“Excellent meeting covering majority of interesting and important topics in malignant hematology”

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

Opportunities are available to companies interested in exhibiting at this conference. For more information, please contact Cori Gunter at +1(678) 242 0712, or by email at c.gunter@imedex.com.

The following companies have provided an educational grant in support of this Congress:

Bronze:

Medimmune

Roche

Corporate:

Mundi Pharma Oncology

Several opportunities are available to companies interested in supporting the Congress. For more information, please contact Imedex at +1 770 751 7332 or by email at cme@imedex.com.